COP vs CTMX · P/E 19, rev $58.94B vs rev $138.1M
ConocoPhillips (COP) versus CytomX Therapeutics Inc (CTMX) — a side-by-side from cached financials, not a winner call.
ConocoPhillips (COP) is a oil & gas e&p company listed on NYSE. It is led by Ryan Lance.
CytomX Therapeutics Inc (CTMX) is a biotechnology company listed on US.
Latest reported COP revenue for 2025-12-31 was $58.94B. Net income was $7.99B. Revenue was up 7.7% from 2024-12-31 to 2025-12-31. COP currently screens at market cap $135.49B and trailing P/E 18.8.
Latest reported CTMX revenue for 2024-12-31 was $138.1M. Net income was $31.9M. Revenue was up 36.4% from 2023-12-31 to 2024-12-31. CTMX currently screens at market cap $653.1M.
COP currently screens at market cap $135.49B and trailing P/E 18.8. CTMX currently screens at market cap $653.1M.
Not investment advice. Open the COP and CTMX stock pages for the full models.
Not investment advice.